Literature DB >> 12241648

Ovarian cancer chemotherapy: carboplatin as standard.

Martin N Tattersall1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12241648     DOI： 10.1016/s0140-6736(02)09757-x

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven.

Authors:  Ruud P M Dings; Emily S Van Laar; Jeremy Webber; Yan Zhang; Robert J Griffin; Stephen J Waters; John R MacDonald; Kevin H Mayo
Journal:  Cancer Lett       Date:  2008-04-01       Impact factor: 8.679

2.  Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer.

Authors:  Yiping Zhang; Furong Huang; Qingyu Luo; Xiaowei Wu; Zhihua Liu; Hongyan Chen; Yinghui Huang
Journal:  Onco Targets Ther       Date:  2018-12-05       Impact factor: 4.147

Review 3.  Primary ovarian cancer chemotherapy: current standards of care.

Authors:  W P McGuire; M Markman
Journal:  Br J Cancer       Date:  2003-12       Impact factor: 7.640

Review 4.  Systems biology of cisplatin resistance: past, present and future.

Authors:  L Galluzzi; I Vitale; J Michels; C Brenner; G Szabadkai; A Harel-Bellan; M Castedo; G Kroemer
Journal:  Cell Death Dis       Date:  2014-05-29       Impact factor: 8.469
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.